SHIPSSNCT03401398
Stress Hydrocortisone In Pediatric Septic Shock
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 61 versions: 48 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 5 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Site details revised at 44 of 44 sites
- Collaborators: details revised at 1 of 4 entries
- Publications: details revised at 3 of 3 entries
- Minor Site details revised at 2 of 44 sitesv60
- Minor Study sites: 51 to 44v59
- Minor Site details revised at 4 of 51 sitesv58
- Minor Site contacts updated at 1 of 51 sites
- Study description shortened, about 1 word
Show 43 earlier versionsHide 43 earlier versions
- Minor Study sites: 52 to 51v56
- Minor Study sites: 51 to 52v55
- Notable Eligibility criteria expanded, about 33 words
- Study sites: 44 to 51
- Study description revised
- Notable Enrollment target: 1032 to 500
- Study sites: 46 to 44
Notable Primary completion date: Sep 30, 2025 to Sep 30, 2026v52 Show 5 more changesShow less
- Primary endpoint revised
- Study completion date: Dec 21, 2025 to Dec 31, 2026
- Secondary endpoint revised
- Study description expanded, about 6 words
- Site details revised at 2 of 46 sites
- Minor Study description expanded, about 13 wordsv51
- Minor Site details revised at 1 of 46 sitesv50
- Notable Eligibility criteria expanded, about 6 words
- Study sites revised (46)
- Minor Study sites: 45 to 46v48
- Minor Site details revised at 1 of 45 sitesv47
- Minor Primary completion date: Jun 30, 2025 to Sep 30, 2025
- Study completion date: Sep 30, 2025 to Dec 21, 2025
- Minor Study sites: 34 to 45v45
- Minor Study sites: 32 to 34v44
- Minor Site contacts updated at 1 of 32 sitesv43
- Minor Site contacts updated at 1 of 32 sitesv42
- Notable Primary completion date: Sep 20, 2024 to Jun 30, 2025
- Study completion date: Dec 30, 2024 to Sep 30, 2025
- Site details revised at 1 of 32 sites
- Notable Primary completion date: Sep 20, 2023 to Sep 20, 2024
- Eligibility criteria expanded, about 3 words
- Study sites: 33 to 32
- Study completion date: Dec 30, 2023 to Dec 30, 2024
- Minor Site details revised at 2 of 33 sitesv39
- Minor Site details revised at 1 of 33 sitesv38
- Minor Study sites: 30 to 33v37
- Minor Study sites: 29 to 30v36
- Minor Site details revised at 1 of 29 sitesv35
- Minor Site details revised at 1 of 29 sitesv34
- Minor Site details revised at 1 of 29 sitesv33
- Minor Site details revised at 1 of 29 sitesv32
- Minor Site details revised at 3 of 29 sitesv31
- Minor Study sites revised (29)v30
- Notable Eligibility criteria expanded, about 27 words
- Study sites: 30 to 29
- Minor Site details revised at 1 of 30 sitesv28
- Minor Site details revised at 1 of 30 sitesv27
- Minor Site details revised at 2 of 30 sitesv26
- Minor Site details revised at 2 of 30 sitesv25
- Minor Site details revised at 2 of 30 sitesv24
- Minor Study sites: 32 to 30v23
- Minor Study sites: 31 to 32v22
- Minor Site details revised at 3 of 31 sitesv21
- Notable Trial status: Suspended to Recruiting
- Site details revised at 31 of 31 sites
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: All sites have been put on hold due to the ongoing COVID-19 pandemic
- Site details revised at 31 of 31 sites
- Minor Site details revised at 1 of 31 sitesv16
- Minor Site details revised at 1 of 31 sitesv15
- Notable Eligibility criteria shortened, about 3 words
- Study description shortened, about 2 words
- Minor Site details revised at 1 of 31 sitesv13
- Minor Site details revised at 1 of 31 sitesv12
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Approximately half of the subjects randomized into SHIPSS will be randomized into the Treatment Group and will receive hydrocortisone sodium succinate according to a predetermined dosing schedule.
Approximately half of the subjects randomized into SHIPSS will be randomized into the Placebo Group and will receive equivalent study drug volumes of normal saline.
Drugs: Hydrocortisone, sodium succinate, Normal saline
Sites
44 sites in 10 countries
United States 18, Canada 10, Israel 3, Malaysia 3, Brazil 2, Japan 2, Pakistan 2, Vietnam 2, Saudi Arabia 1, Singapore 1